Incyte To Seek Another Monjuvi Approval In Crowded CD19-Targeting Market

Interest Growing Across Indications

Incyte reported positive topline Phase III results for Monjuvi in relapsed or refractory follicular lymphoma and plans to file for US FDA approval by the end of 2024.

Business candle stick graph chart of stock market investment trading on blue background
Follicular lymphoma may help Monjuvi revenue grow into the hundreds of millions of dollars • Source: Shutterstock

Incyte Corporation reported positive topline results from the Phase III inMIND clinical trial of its CD19-targeting monoclonal antibody Monjuvi (tafasitamab) in relapsed or refractory follicular lymphoma (FL) on 16 August and said it will file a supplemental biologics license application (sBLA) with the US Food and Drug Administration for the indication by the end of this year. FL is one of two indications the company is targeting for near- to mid-term growth in an increasingly crowded drug class.

Key Takeaways
  • Incyte plans to seek US FDA approval for Monjuvi in relapsed or refractory follicular lymphoma (FL) by the end of 2024 based on positive topline results from the inMIND study.

In February, Wilmington, DE-based Incyte agreed to pay $25m to obtain exclusive global rights to Monjuvi from its partner

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Clinical Trials

Boehringer Ingelheim Expects Two Key Approvals In Second Half Of 2025

 

The privately held German pharma firm is hoping to bring a new generation of pulmonary fibrosis and cancer drugs to market but their commercial success is not yet a certainty.

Memo Therapeutics Plans BK Virus Therapy Phase III Despite Trial Miss

 
• By 

Pointing to data that show a benefit in reducing viral load and the histological signs of the infection, Memo says its drug, potravitug, could become the first therapy to treat BK polyomavirus in kidney transplant recipients.

AZ Poised To Bring Self-Administered C5 Inhibitor To Market

 

Gefurulimab will give AstraZeneca a new option to compete against Argenx’s Vyvgart Hytrulo, which is available subcutaneously.

Leo Looks To Grow In US After Hand Eczema Cream Approval

 
• By 

The Danish medical dermatology specialist doubles boosts its sales force ahead of the launch of Anzupgo.

More from R&D

AZ Poised To Bring Self-Administered C5 Inhibitor To Market

 

Gefurulimab will give AstraZeneca a new option to compete against Argenx’s Vyvgart Hytrulo, which is available subcutaneously.

Leo Looks To Grow In US After Hand Eczema Cream Approval

 
• By 

The Danish medical dermatology specialist doubles boosts its sales force ahead of the launch of Anzupgo.

Obesity Beyond GLP-1s: Amylins – The Next Frontier

 
• By 

In this series of articles, we look at different mechanisms of actions beyond GLP-1s that could determine the obesity drug landscape in the coming years. First on our list – amylin receptor agonists, which analysts expect to grow into a $50bn market opportunity.